William practices in the Corporate & Securities Section and is based in the New York office. Prior to joining Mintz Levin, he was a partner at another major Boston law firm. He focuses his practice on public offerings, CMPOs, registered directs, PIPEs, private placements, venture capital investments, mergers and acquisitions, corporate governance, reporting, and providing general corporate counsel. The clients he represents include investment banks, investors, issuers, and venture capital firms as well as clients in the life sciences and telecommunications industries. He has also provided cross-border counsel to foreign companies in Europe, North America, South Asia, and other emerging markets. William is admitted to practice in Massachusetts. He received his J.D. from the University of Southern California Law School, his M.A. from King's College London, and his B.A. from Yale University. Representative Matters ˇ Represented life sciences investment banks and other life sciences investors in underwritten public offerings, CMPOs, registered directs, PIPEs, and private placements ˇ Prepared engagement letters for a life sciences investment bank ˇ Represented venture capital firms in life sciences investments in the United States, Japan, and the Cayman Islands ˇ Represented a U.S.-based venture capital fund in $60 million investment in a foreign biotech company ˇ Represented issuers in the plant genomics, online retailing, and genetics industries in IPOs ˇ Represented a Canadian oncology issuer with its U.S. listing and registration ˇ Represented a European medical device company being in its acquisition by a publicly traded company based in the United States ˇ Represented a European company in the sale of a business unit to a U.S. company ˇ Represented an Australian company in establishing exemptions to the Securities Act, Exchange Act, and blue sky laws ˇ Represented a European issuer in the sale of a business to one of its investors ˇ Represented companies in the online services, life sciences, vision care, and exhibit design/construction industries in merger and acquisition transactions ˇ Represented underwriters in public offerings by issuers in the medical device and genomics industries ˇ Represented a European biotech company, major online services company, and vision care company in follow-on public offerings ˇ Represented biotech companies in public offerings, registered directs, PIPEs, and Rule 144A debt and equity offerings Recent Mentions ˇ Quoted, "Opportunity vs. Vulnerability In New Fundraising Initiatives," BioWorld Insight, December 5, 2011 ˇ Quoted, "Crowd-Funding is Coming, But Will it Be Niche Only?," BioWorld Insight, November 28, 2011 ˇ Quoted, "Creating an IPO Alternative for Small Biotechs," BioWorld Insight, November 21, 2011 ˇ Quoted, "Viva La Revolucion: Reg-A, Crowd-Funding Bills Expand Options for Biotechs," BioWorld Insight, November 14, 2011 ˇ Quoted, "NASDAQ Rejects Structure to Skirt 20% Rule, Attorneys Say," PIPEs Report, June 15, 2010 ˇ Quoted, "FINRA Redoubles Focus on Due Diligence," PIPEs Report, May 4, 2010 ˇ Quoted, "SEC Clarifies Rule 415, Attorneys Say," PIPEs Report, April 6, 2010 ˇ Quoted, "Gresham's Got Talent with All-cash Agency Deal," Financial News Online, July 31, 2009 ˇ Quoted, "Lacking Leverage, Firms Embrace EBOs," Wall Street Journal, March 11, 2009 ˇ Co-author, "Unblocking Clogged PIPEs: SEC Focuses on Availability of Rule 415," Insights, May 1, 2007 Speaking Engagements ˇ Panelist, "Creative Structures for Getting Deals Done in a Challenging Environment," The PIPES Conference 2011, New York (November 2011) Industries Life Sciences (Also at New York, New York Office) |